Interestingly, in the subgroup of patients who were randomly allocated to receive adjuvant imatinib for 36 months, GIST FGL2 expression had little influence on RFS (HR = 0.92, 95% CI: 0.48–1.77), whereas in the subgroup of patients allocated to receive imatinib for 12 months, patients with FGL2‐positive GIST had substantially better RFS as compared to those with FGL2‐negative GIST (HR = 0.52, 95% CI 0.32–0.86, Figure 2F). This evidence concerns the gene FGL2 and gastrointestinal stromal tumor.